将重症监护病房１１９例继发肺部感染病人随机分成两组，分别给予硫酸奈替米星３００ｍｇ／ｄ或阿米卡星６００ｍｇ／ｄ治疗，根据临床表现、白细胞计数、痰培养、胸片及肝肾功能等其它辅助检查，观察其疗效及不良反应。结果显示：硫酸奈替米星有效率（７９．７％）比阿米卡星（５７．８％）高；辅助检查中白细胞计数、胸片恢复正常率和痰培养转阴率前组均高于后组，而不良反应前组低于后组。本文认为：对重症监护病房肺部感染初期，痰培养及药敏尚未确定的病人，给予硫酸奈替米星３００ｍｇ／ｄ短程治疗是有效且安全的方案，尤其对老年人、小儿和有轻度肾功能损害者，在严密肾功能监护下，可有针对性使用，故硫酸奈替米星具有较大的临床使用价值 119 cases of secondary pulmonary infection in intensive care unit were randomly divided into two groups, respectively, given netilmicin sulfate 300mg / d or amikacin 600mg / d treatment, according to clinical manifestations, white blood cell count, sputum culture, chest and Liver and kidney function and other auxiliary examination to observe the efficacy and adverse reactions. The results showed that the effective rate of netilmicin sulfate (79.7%) was higher than that of amikacin (57.8%); the white blood cell count, the normal rate of chest X-ray recovery and the negative rate of sputum culture were higher In the latter group, while the adverse reactions before the group was lower than the latter group. This paper argues that it is an effective and safe way to give netilmicin sulfate 300 mg / d for patients with initial stage lung infection in initial ICU and sputum culture and drug susceptibility has not been determined, especially for the elderly, children and mild Kidney damage, under the supervision of renal function can be targeted, so netilmicin sulfate has a greater clinical value